Home

Andrew Reardon

CIK 1950232 · CLO & Secretary · last filed 2026-09-08

Andrew Reardon is a CLO & Secretary who has filed 36 SEC Form 4 insider transactions across 1 company since 2022. The most recent filing shows the insider sold $1.4M of LGND on Sep 8, 2026. Across all open-market trades the lifetime net is −$10.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $11.4M across reported positions. 35 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$11.43M

Companies

1

Total Filings

36

Lifetime Open-Market Net

-$10.20M

Filer Profile

Reported Address
C/O LIGAND PHARMACEUTICALS INCORPORATED
3911 SORRENTO VALLEY BLVD, SUITE 110
SAN DIEGO, CA 92121
Related Filers
LIGAND PHARMACEUTICALS INC — 35 joint filings, latest 2026-08-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LGND CLO & Secretary 39,414 $290.07 $11.43M -$10.20M 27 2026-09-08

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-08 LGND Sell (S) −5,000 -$1.43M EDGAR
2026-09-03 LGND Notice (144) −15,000 -$4.30M EDGAR
2026-08-04 LGND Mixed — -$1.18M EDGAR
2026-07-06 LGND Mixed +132 -$1.28M EDGAR
2026-07-01 LGND Notice (144) −10,000 -$3.16M EDGAR
2026-06-02 LGND Mixed — -$874.0K EDGAR
2026-05-04 LGND Mixed — -$895.2K EDGAR
2026-04-02 LGND Mixed — -$744.9K EDGAR
2026-03-27 LGND Grant (A) +4,513 $0 EDGAR
2026-03-06 LGND Mixed — -$770.4K EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.